Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm

C

Creighton University

Status and phase

Completed
Phase 4

Conditions

Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis

Treatments

Genetic: Warfarin Dose based on pharmacogenetics

Study type

Interventional

Funder types

Other

Identifiers

NCT00511173
06-14171

Details and patient eligibility

About

This is a prospective comparison of clinician dosing and a pharmacogenetic algorithm in diagnosed patients requiring warfarin therapy.

Full description

Diagnosed patients with atrial fibrillation, pulmonary embolism, or deep venous thrombosis requiring warfarin therapy will be consented and a tube of blood for DNA analysis will be drawn. The clinician dosing group will not be eligible to obtain the pharmacogenetic results and the algorithm group will have their warfarin pharmacogenetic SNPs performed and integrated into the algorithm and the warfarin dose will be calculated. Outcomes of patients receiving both methods will be gathered and statistically analyzed.

Enrollment

102 patients

Sex

All

Ages

19 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed patients with atrial fibrillation, deep venous thrombosis, or pulmonary embolism requiring warfarin therapy

Exclusion criteria

Patients with atrial fibrillation, deep venous thrombosis, or pullmonary embolism requiring warfarin therapy who do not consent to participate

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

102 participants in 1 patient group

Clinician dosing of warfarin
Experimental group
Description:
Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
Treatment:
Genetic: Warfarin Dose based on pharmacogenetics

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems